Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.

Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y

[img] Text
Publikation Melphalan.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (913kB) | Request a copy

The optimal melphalan dose prior to autologous stem cell transplantation (ASCT) is not known for elderly multiple myeloma (MM) patients. We analyzed data of all MM patients ≥65 years (n = 388) enrolled in the observational Swiss Blood Stem Cell Transplantation Registry. The median age was 67 years (65-77). Single ASCT was performed in 344 (88.7%) patients, with 259 patients (75.3%) receiving a melphalan dose of 200 mg/m (MEL200), and 85 patients (24.7%) receiving lower doses (MELlow) (median 140 mg/m, range 70-180 mg/m). MEL200 patients were slightly younger, and had a better renal function, but did not differ with regards to ISS stage, cytogenetic risk, remission status, and KPS. Overall mortality at day 100 was 1.5% without differences between the MEL groups (p = 0.621). Median progression-free survival (PFS) in the MEL200 and the MELlow group was 27.7 and 22.1 months, respectively (p = 0.294). Median overall survival (OS) in the MEL200 and in MELlow group was 91.2 and 61.2 months (p = 0.015). However, multivariate analysis showed no significant association of the melphalan dose and OS (HR 0.734; CI95% 0.264-2.038; p = 0.553). In conclusion, our data reveal no significant differences in safety and PFS for elderly myeloma patients treated with MEL200 or with lower MEL doses.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas Niklaus, Jeker, Barbara

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0268-3369

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

22 Feb 2019 08:41

Last Modified:

02 Mar 2023 23:31

Publisher DOI:

10.1038/s41409-018-0379-y

PubMed ID:

30390061

BORIS DOI:

10.7892/boris.123975

URI:

https://boris.unibe.ch/id/eprint/123975

Actions (login required)

Edit item Edit item
Provide Feedback